학술논문
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Document Type
article
Author
Chung, Raymond T; Ghany, Marc G; Kim, Arthur Y; Marks, Kristen M; Naggie, Susanna; Vargas, Hugo E; Aronsohn, Andrew I; Bhattacharya, Debika; Broder, Tina; Falade-Nwulia, Oluwaseun O; Fontana, Robert J; Gordon, Stuart C; Heller, Theo; Holmberg, Scott D; Jhaveri, Ravi; Jonas, Maureen M; Kiser, Jennifer J; Linas, Benjamin P; Re, Vincent Lo; Morgan, Timothy R; Nahass, Ronald G; Peters, Marion G; Reddy, K Rajender; Reynolds, Andrew; Scott, John D; Searson, Gloria; Swan, Tracy; Terrault, Norah A; Trooskin, Stacey B; Wong, John B; Workowski, Kimberly A
Source
Clinical Infectious Diseases. 67(10)
Subject
Language
Abstract
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or research data. A major update was released electronically in September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance's scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendations herein were developed by volunteer hepatology and infectious disease experts representing AASLD and IDSA and have been peer reviewed and approved by each society's governing board.